Insurance Company Requirements Place Heavy Administrative Burden on Physicians Seeking to Prescribe New Cholesterol-Lowering Drugs
Perelman School of Medicine at the University of PennsylvaniaA rare glimpse into the prior authorization requirements implemented by public and private insurance providers across the country has found substantial administrative burden for a new class of medications for patients with high cholesterol that places them at high risk for heart attack or stroke. So-called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are self-injected medications approved for individuals with a genetic condition called familial hypercholesterolemia (FH) and those with atherosclerotic cardiovascular disease (ASCVD) who have high cholesterol despite receiving traditional statin medications and other treatments. Results of the study are published in Circulation: Cardiovascular Quality and Outcomes.